Chemistry:Sovaprevir
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Other names | ACH-1625 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| NIAID ChemDB | |
| Chemical and physical data | |
| Formula | C43H53N5O8S |
| Molar mass | 799.98 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.[1] Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012.[2]
References
- ↑ "Current race in the development of DAAs (direct-acting antivirals) against HCV". Biochemical Pharmacology 89 (4): 441–52. June 2014. doi:10.1016/j.bcp.2014.04.005. PMID 24735613.
- ↑ "Sovaprevir HCV NS3/4A Protease Inhibitor". Achillion. http://www.achillion.com/sovaprevir_ACH1625.
External links
